- Conditions
- Influenza, COVID-19, Vaccination Willingness
- Interventions
- Survey
- Other
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 1,164
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza A
- Interventions
- VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 129
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
- Conditions
- Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
- Interventions
- Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
- Dietary Supplement
- Lead sponsor
- Quantec Ltd
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Influenza, Human
- Interventions
- D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 470 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
- Conditions
- HIV Infections
- Interventions
- Interleukin-2
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza
- Interventions
- Influenza A Vaccine: ACAM FLU-A, Saline placebo
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 3
- States / cities
- Miami, Florida • Lenexa, Kansas • Tacoma, Washington
- Conditions
- Influenza, COVID-19
- Interventions
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Years to 64 Years
- Enrollment
- 455 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 4 more
- Conditions
- Influenza, SARS-CoV-2
- Interventions
- mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
- Conditions
- Influenza
- Interventions
- MF59-eH1N1_f
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,719 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more
- Conditions
- Cytomegalovirus Infections, Influenza
- Interventions
- Fluzone® 2012-2013 Formula NDC No 498281-012-50
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Severe Sepsis
- Interventions
- Not listed
- Lead sponsor
- Bluejay Diagnostics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 200 participants
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Influenza A Virus, H1N1 Subtype, Novel Swine-Origin
- Interventions
- VRC-FLUDNA057-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza
- Interventions
- Liquid CAIV-T
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 6 Months to 59 Months
- Enrollment
- 8,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 107
- States / cities
- Hoover, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 96 more
- Conditions
- Influenza
- Interventions
- VAX125
- Biological
- Lead sponsor
- VaxInnate Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Influenza
- Interventions
- Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
- Conditions
- Vaccine Hesitancy
- Interventions
- EHR alert, Motivational Interviewing, Warm hand off to nurse
- Other · Behavioral
- Lead sponsor
- Boston College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,698 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Influenza
- Interventions
- Oseltamivir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 12 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
- Conditions
- Vaccination
- Interventions
- Control Site, Intervention Site, Patient-level Control Group, Patient-level Intervention Group
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 2,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 12 more
- Conditions
- Influenza
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- CP-690,550, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 51
- States / cities
- Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
- Conditions
- COVID-19, Influenza
- Interventions
- GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
- Device · Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Seasonal Influenza
- Interventions
- VXA-A1.1
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Immunization Status Among Obstetrics and Gynecology Patients
- Interventions
- Multimodal Vaccine Program
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years and older · Female only
- Enrollment
- 97,087 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Allergic Rhinitis
- Interventions
- live attenuated influenza virus (LAIV) with clean air, LAIV and diesel exhaust particles
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina